Results 11 to 20 of about 1,065 (178)

ROLE OF THE KNOWN MUCOLYTICS IN MUCOVISCIDOSIS THERAPY

Педиатрическая фармакология, 2014
The primary objective in the mucoviscidosis therapy is to ensure normal rheology of respiratory secretion for effective evacuationthereof from the bronchial tree and nasal sinuses.
O. I. Simonova, Yu. V. Gorinova
doaj   +3 more sources

COMPLEX THERAPY OF CHILDREN WITH MUCOVISCIDOSIS. RECOMMENDATIONS OF A PEDIATRICIAN

Педиатрическая фармакология, 2006
Treatment of children's mucoviscidosis is a multicomponent complex of medical and non medicamental types of therapy. The earlier the basic mucoviscidosis treatment has started, the more favourable the diagnosis for the patient will be.
O.I. Simonova
doaj   +3 more sources

VIRAL INFECTIONS IN CHILDREN SUFFERED FROM CISTIC FIBROSIS

Педиатрическая фармакология, 2011
Results of study of antiviral immunity indicators in patients with mucoviscidosis were presented. A significant antibody deficiency against a number of antigenically unrelated viruses — acute respiratory pathogens and Мycoplasma pneumonia, significantly ...
N.N. Nisevich, E.V. Sereda, N.S. Selyutina, O.V. Kriger, I.N. Nikishtsev, N.L. Agoshkova   +5 more
doaj   +4 more sources

PSYCHOLOGICAL-PEDAGOGICAL ASPECTS OF TREATING CHILDREN WITH MUCOVISCIDOSIS

Педиатрическая фармакология, 2014
The article is dedicated to optimization of psychological help rendering to children with mucoviscidosis. The authors emphasize the need in multidisciplinary approach to rehabilitation of such children and present results of a study of psychological ...
T. V. Sviridova, A. M. Timofeyeva, O. I. Simonova, S. B. Lazurenko   +3 more
doaj   +4 more sources

THE REGISTER AS A MEANS OF IMPROVING THE QUALITY OF MUCOVISCIDOSIS PATIENTS’ TREATMENT

Педиатрическая фармакология, 2012
The creation of a register of mucoviscidosis (MV) patients is necessary for determining the epidemic situation in the region, evaluating the efficacy of therapeutic strategies and the quality of healthcare provided.
I. K. Asherova, N. I. Kapranov
doaj   +3 more sources

A Cross-Sectional Analysis of Paternal Intimacy Problems, Stress Levels, and Satisfaction from Families with Children Born with Mucoviscidosis. [PDF]

Int J Environ Res Public Health, 2022
There is an increasing interest in father–child interactions and their effects. Due to the rising number of working mothers, marital interruptions, divorces, and child custody arrangements, paternal duties and the relevance of fathering continue to
Popa ZL, Margan MM, Bernad E, Stelea L, Craina M, Ciuca IM, Bina AM.   +6 more
europepmc   +2 more sources

Citrus Flavonoids for Cystic Fibrosis Treatment. [PDF]

Chembiochem
Studies conducted since the late 1990s show substantial activity of selected citrus flavonoids as cystic fibrosis transmembrane conductance regulator (CFTR) membrane protein activators. The thesis of this work is that aptly formulated citrus flavonoids hold sigificant potential for developing a multitarget treatment of cystic fibrosis combining in a ...
Pagliaro M, Di Sano C, D'Anna C, Li Petri G, Angellotti G, Ciriminna R.   +5 more
europepmc   +2 more sources

Endoscopically assessed mucus parameters in equine asthma: Relationship to clinical history and cytological findings data. [PDF]

Equine Vet J
Abstract Background Mucus parameters are hallmark diagnostic features of equine asthma (EA). Objectives To investigate the relationship between mucus quantity score and mucus viscosity score with signalment, history, clinical findings and cytological parameters. Study Design Retrospective cross‐sectional study.
Drespling J, Berwanger L, Kühn H, Schwarz B, Doherr M, Mundhenk L.   +5 more
europepmc   +2 more sources

Draft Genome Sequence of Chryseobacterium mucoviscidosis sp. nov. Strain VT16-26, Isolated from the Bronchoalveolar Lavage Fluid of a Patient with Cystic Fibrosis. [PDF]

Genome Announc, 2018
We report here the draft genome sequence of Chryseobacterium mucoviscidosis VT16-26, a novel bacterium isolated from the lungs of a patient with cystic fibrosis.
Tetz G, Tetz V.
europepmc   +2 more sources

Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review

Medical Journal of Australia, Volume 219, Issue 10, Page 496-502, November 2023., 2023
Summary Cystic fibrosis is a monogenic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which transports chloride ions in secretory organs. Modulator therapies are small molecules that correct CFTR dysfunction and can lead to a wide range of benefits for both pulmonary and extrapulmonary ...
Shanal Kumar, Georgia Soldatos, Helena J Teede, Michael Pallin   +3 more
wiley   +1 more source